On July, 18 Sarepta Therapeutics, Inc. (SRPT) Analysts See $-0.57 EPS

June 27, 2018 - By Fidelia Bagby

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Corporate Logo
Big Money Sentiment decreased to 0.97 in 2018 Q1. It has change of 0.25, from 2017Q4’s 1.22. The ratio turned negative due to Sarepta Therapeutics, Inc. positioning: 31 sold and 81 reduced. 45 funds bought stakes and 64 increased stakes. Investors holded 52.88 million in 2017Q4 but now own 54.74 million shares or 3.52% more.
Great West Life Assurance Can holds 6,948 shs or 0% of its capital. Mufg Americas holds 0% in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) or 220 shs. Public Employees Retirement Association Of Colorado has 10,545 shs for 0.01% of their capital. Elk Creek Partners Ltd Liability Corp has 1.41% invested in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). Aperio Group Inc Lc has invested 0% in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). Raymond James Assoc holds 0% or 24,310 shs. Northern Trust Corporation accumulated 713,759 shs or 0.01% of the stock. 8,140 are owned by Amalgamated Retail Bank. Quantitative Systematic Strategies Ltd Liability Corporation holds 0.06% or 3,529 shs. The Ontario – Canada-based Td Asset Mgmt Incorporated has invested 0.01% in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). Stonebridge Mngmt owns 2,870 shs. Amer Gp reported 39,065 shs stake. Hall Laurie J Trustee holds 0% or 90 shs in its capital. Jane Street Gru Lc holds 0.01% of its capital in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) for 26,287 shs. Bnp Paribas Arbitrage owns 17,582 shs or 0% of their US capital.

On July, 18 Sarepta Therapeutics, Inc. (NASDAQ:SRPT)’s earnings report is awaited by WallStreet, Zacks reports. Analysts forecast 50.43 % diference or $-0.57 from the $-1.15 EPS from 2017. 29.55 % negative EPS growth is what analysts predict. $-0.44 EPS was reported for last quarter. SRPT is reaching $130.53 during the last trading session, after decreased 3.69%.Currently Sarepta Therapeutics, Inc. is uptrending after 197.08% change in last June 27, 2017. SRPT has also 768,120 shares volume. SRPT outperformed the S&P500 by 184.51%.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Ratings Coverage

A total of 20 analysts rate Sarepta Therapeutics (NASDAQ:SRPT) as follows: 18 “Buy”, 2 “Hold” and 0 “Sell”. Тherefore 90% are bullish. (NASDAQ:SRPT) has 36 ratings reports on Jun 27, 2018 according to StockzIntelligence. On Wednesday, March 7 the stock has “Buy” rating by SunTrust. The company rating was maintained by Piper Jaffray on Monday, March 12. On Friday, March 2 the firm has “Buy” rating given by Piper Jaffray. In Wednesday, June 20 report Morgan Stanley maintained the stock with “Equal-Weight” rating. The stock rating was maintained by Robert W. Baird with “Buy” on Thursday, June 21. The company rating was maintained by Morgan Stanley on Friday, May 4. On Wednesday, March 14 the firm has “Overweight” rating given by JP Morgan. On Wednesday, June 20 the stock has “Buy” rating by WBB Securities. On Thursday, March 15 the company was maintained by SunTrust. On Friday, May 4 the rating was maintained by Credit Suisse with “Outperform”.

Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA therapeutics for the treatment of rare neuromuscular diseases.The company has $8.55 billion market cap. The firm offers EXONDYS 51, a disease-modifying therapy for the treatment of duchenne muscular dystrophy , which is a rare genetic muscle-wasting disease caused by the absence of dystrophin.Currently it has negative earnings. It also develops SRP-4045 and SRP-4053, which are exon skipping clinical product candidates for the treatment of DMD.

For more Sarepta Therapeutics, Inc. (NASDAQ:SRPT) news released recently go to: Fool.com, Fool.com, Seekingalpha.com, Fool.com or Seekingalpha.com. The titles are as follows: “Are These 3 Red-Hot Gene Therapy Stocks Still Buys?” released on June 25, 2018, “Is Sarepta Therapeutics Stock Headed to Over $200 a Share?” on June 21, 2018, “Sarepta Therapeutics: Chasing The Good News” with a publish date: June 21, 2018, “Why Sangamo Therapeutics Stock Is Spiking Today” and the last “Sarepta: A Lesson In Unpredictability” with publication date: June 27, 2018.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: